Self-Assembled Polymeric Micellar Nanoparticles as Nanocarriers for Poorly Soluble Anticancer Drug Ethaselen

Table 3 In vivo antitumor effect of ethaselen-loaded mPEG5-PLA2.5 micelle and ethaselen-HP-β-CD in H₂₂human liver cancer cell bearing mice model (,n = 10)

Formulation	Dose (mg/kg)	Body weight (g)		Tumor weight (g)	Inhibition rate (%)
Formulation	Dose (mg/kg)	Before administration	After administration	Tumor weight (g)	Inhibition rate (%)
Physiological saline	0	20.38 ± 0.94	28.01 ± 2.24	1.29 ± 0.26	–
Ethaselen-HP-β-CD	1	19.94 ± 0.86	26.94 ± 2.11*	0.81 ± 0.13*	36.93
Ethaselen-micelle (L)	1	20.52 ± 0.66	28.10 ± 1.65	0.71 ± 0.12^,*	45.10
Ethaselen-micelle (M)	2	20.92 ± 0.58	28.75 ± 1.76	0.57 ± 0.17^,^,**	55.60
Ethaselen-micelle (H)	4	20.20 ± 0.42	28.42 ± 1.81	0.53 ± 0.11^,^,^,**	58.47

* p < 0.05, versus physiological saline; ** p < 0.05, versus ethaselen-HP-β-CD; *** p < 0.05, versus ethaselen-micelle (L); **** p > 0.05, versus ethaselen-micelle (M)